Clofarabine
- Generic Name
- Clofarabine
- Brand Names
- Clolar, Evoltra
- Drug Type
- Small Molecule
- Chemical Formula
- C10H11ClFN5O3
- CAS Number
- 123318-82-1
- Unique Ingredient Identifier
- 762RDY0Y2H
- Background
Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaemia (ALL), only after at least two other ...
- Indication
For the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphocytic (lymphoblastic) leukemia after at least two prior regimens. It is designated as an orphan drug by the FDA for this use.
- Associated Conditions
- Refractory Acute Lymphoblastic Leukemia (ALL), Refractory Acute Myeloid Leukemia (AML), Relapsed Acute Lymphoblastic Leukemia (ALL), Refractory Langerhans cell histiocytosis
- Associated Therapies
- -
Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
- First Posted Date
- 2012-05-11
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 16
- Registration Number
- NCT01596699
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match
- Conditions
- Interventions
- First Posted Date
- 2011-12-28
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- Texas Oncology Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT01500161
- Locations
- 🇺🇸
Texas Oncology, Amarillo, Texas, United States
Fludarabine-IV Busulfan ± Clofarabine and Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
- First Posted Date
- 2011-11-15
- Last Posted Date
- 2021-12-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 256
- Registration Number
- NCT01471444
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Cord Blood Fucosylation to Enhance Homing and Engraftment in Patients With Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT01471067
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2011-10-13
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT01451515
- Locations
- 🇺🇸
Rady Children's Hospital San Diego, San Diego, California, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Clofarabine Plus Low-Dose Cytarabine for Patients With Higher-Risk Myelodysplastic Syndrome (MDS)
- Conditions
- Interventions
- First Posted Date
- 2011-10-03
- Last Posted Date
- 2018-07-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 81
- Registration Number
- NCT01444742
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Clofarabine Pre-conditioning With Allogeneic Transplant for Acute Myeloid Leukaemia (AML)
- First Posted Date
- 2011-08-24
- Last Posted Date
- 2018-09-07
- Target Recruit Count
- 9
- Registration Number
- NCT01422603
- Locations
- 🇬🇧
Wessex Blood and Marrow Transplant Unit, Southampton University Hospitals NHS Trust, Southampton, Hampshire, United Kingdom
Clofarabine Salvage Therapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- First Posted Date
- 2011-02-14
- Last Posted Date
- 2015-10-07
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 86
- Registration Number
- NCT01295307
- Locations
- 🇩🇪
HELIOS Klinikum Bad Saarow, Bad Saarow, Germany
🇩🇪Klinikum Mannheim GmbH, Mannheim, Germany
🇩🇪University Hospital Carl Gustav Carus, Dresden, Germany
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2011-02-03
- Last Posted Date
- 2020-02-24
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 282
- Registration Number
- NCT01289457
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Safety of Clofarabine With Multiagent Chemotherapy in Childhood Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2011-01-19
- Last Posted Date
- 2014-12-09
- Lead Sponsor
- University Hospital, Lille
- Target Recruit Count
- 20
- Registration Number
- NCT01279096
- Locations
- 🇫🇷
Besançon University Hospital, Besançon, France
🇫🇷Lille University Hospital, Lille, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.